Ovarian Cancer | Specialty

Low Response Rates Halt First Trial of Abiraterone in Ovarian Cancer

October 17th 2016

The first trial evaluating the efficacy of abiraterone in patients with ovarian cancer has been halted early due to low response, according to results from the CORAL phase II trial, which were presented at the European Society for Medical Oncology Congress.

Counting to 125: The Painstaking Journey to a Landmark Ovarian Cancer Biomarker

October 11th 2016

Robert C. Bast Jr, MD, who led the development of the first clinically relevant blood-based biomarker for ovarian cancer, was honored in the Gynecologic Malignancies category with a 2015 Giants of Cancer Care® award, a program that OncLive launched to recognize leaders in the field.

Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer

October 9th 2016

Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.

Antibody-Drug Conjugate Active in Pretreated Ovarian Cancer

October 9th 2016

A fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7.

Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer

October 8th 2016

Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.

High Response Rates With Rucaparib in Heavily Pretreated Ovarian Cancer

October 7th 2016

The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.

Dr. Bergstrom on XMT-1536 in Ovarian Cancer

October 5th 2016

Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.

Dr. Markman on Important Factors of BSO in Ovarian Cancer

October 3rd 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the most important factors of bilateral salpingo-oophorectomy (BSO) to convey to patients with ovarian cancer.

Dr. LoRusso on PARP Inhibitors in Triple-Negative Breast Cancer

September 30th 2016

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.

Dr. Charlie Gourley on Olaparib Maintenance in Ovarian Cancer

September 20th 2016

Expert Sheds Light on Important Variables in Preventive Surgery in Ovarian Cancer

September 14th 2016

Several variables are important to consider when undergoing preventive surgery for ovarian cancer, including familial history and age.

Tesaro Initiates Rolling Submission for Niraparib in Ovarian Cancer

September 12th 2016

The FDA has granted a fast track designation to niraparib, allowing the initiation of a rolling submission of data for potential approval for the PARP inhibitor as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Markman on Timing of BSO in Patients With Ovarian Cancer

September 12th 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).

Neoadjuvant Chemo Optimal Choice for Some Women With Ovarian Cancer

September 8th 2016

Neoadjuvant chemotherapy is likely the optimal treatment choice for some women with newly diagnosed advanced ovarian cancer, while other patients should receive primary cytoreductive surgery.

Dr. Leslie M. Randall on Early BRCA Testing in Ovarian Cancer

September 2nd 2016

Dr. Robert Coleman on BRCA Testing in Ovarian Cancer

August 27th 2016

Benefit of Maintenance Olaparib in Patients With Ovarian Cancer

August 25th 2016

Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discusses a study comparing the use of olaparib (Lynparza) after chemotherapy with placebo after chemotherapy in patients with platinum-sensitive ovarian cancer.

FDA Grants Rucaparib Priority Review in Ovarian Cancer

August 24th 2016

The FDA has granted a priority review to a new drug application for rucaparib as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.

Early Results Show Niraparib/Bevacizumab Combo Is Safe in Relapsed Ovarian Cancer

August 19th 2016

Results of a phase I trial demonstrate that the combination of niraparib and bevacizumab (Avastin) can be safely administered to patients with platinum-sensitive relapsed ovarian cancer.

"True" Genomic Drivers of Ovarian Cancer Not Yet Identified, NCI Researcher Says

August 17th 2016

Christina M. Annunziata, MD, PhD, has been instrumental in the genomic profiling of ovarian cancers and in elucidating the molecular pathways that are central to this disease.